Retifanlimab
Programmed Death Receptor-1 Blocking Antibody — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Also known as: AEX1188, INCMGA00012, MGA012, retifanlimab-dlwr, zynyz
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Retifanlimab is a drug in the Programmed Death Receptor-1 Blocking Antibody class catalogued in DrugCentral. It was first approved by the FDA in 2023. Its mechanism of action is classified as Programmed Death Receptor-1-directed Antibody Interactions. DrugCentral lists 1 molecular target, including PDCD1. Recorded indications include Merkel cell carcinoma.
- Drug class: Programmed Death Receptor-1 Blocking Antibody.
- Mechanism of action: Programmed Death Receptor-1-directed Antibody Interactions.
- Molecular targets: PDCD1 (1 listed in DrugCentral).
- Indications: Merkel cell carcinoma.
- ATC code: L01FF10 (PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors).
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Merkel cell carcinoma
Mechanism & targets
| Mechanism of action (MoA) | Programmed Death Receptor-1-directed Antibody Interactions |
|---|---|
| Established pharmacologic class | Programmed Death Receptor-1 Blocking Antibody |
Molecular targets (1)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Programmed cell death protein 1 | PDCD1 | other | Kd 9.22 |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2023-03-22 | FDA | — | INCYTE CORP | Yes |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
L01FF10 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES › PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors |
Chemical structure
| Molecular formula | — |
|---|---|
| Molecular weight | — |
| CAS number | 2079108-44-2 |
| InChIKey | — |
| PubChem CID | — |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Retifanlimab used for?
DrugCentral lists the following indications for Retifanlimab: Merkel cell carcinoma.
How does Retifanlimab work?
Retifanlimab is classified as Programmed Death Receptor-1-directed Antibody Interactions; its molecular targets in DrugCentral include PDCD1.
When was Retifanlimab first approved?
Retifanlimab was first approved by the FDA in 2023.
What drug class does Retifanlimab belong to?
Retifanlimab is in the Programmed Death Receptor-1 Blocking Antibody class.
Browse: all drugs starting with R · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 5719 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL4298037 — compound record and bioactivity
- DrugBank DB15766 — drug record
- FDA UNII 2Y3T5IF01Z — substance identity
- DailyMed: FDA labels for Retifanlimab — current prescribing information (label search)
- UniProt Q15116 (PDCD1) — target protein
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.